Sarepta could be down on patient death in FDA database, says RBC Capital
In This Article:
RBC Capital analyst Brian Abrahams says shares of Sarepta (SRPT) could be trading lower today on an FDA database update that included am Elevidys patient death, which occurred in November in a patient who experienced muscle spasms and mylagia.
Invest with Confidence:
-
Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
-
Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SRPT:
Terms and Privacy Policy